By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The Sudanese government has recently decided to gradually replace imported medicines with local alternatives, in the hope of reviving the national pharmaceutical industry.
The decision first aims to encourage the local pharmaceutical industry by gradually stopping the imports of medicines that are manufactured locally.
Official statistics indicate that the country imports medicines worth more than 200 million U.S. dollars a year, while local medicines account for 40 percent of local market demand.
Sudan’s population is expected to reach 55.5 million by 2027, which will create a larger market for pharmaceutical products.
The prevalence of chronic diseases such as diabetes, cardiovascular disease, and cancer is increasing in Sudan, which is driving demand for pharmaceuticals.
The Sudanese government is encouraging investments in the pharmaceutical industry, which could help to grow the market.
There is a significant unmet need for pharmaceutical products in rural areas of Sudan. Pharmaceutical companies could expand into these areas to tap into this growing market.
There is a lack of innovative pharmaceutical products developed specifically for Sudanese patients. Pharmaceutical companies could invest in research and development to create new products tailored to the needs of the Sudanese population.
Sanofi has partnered with the Sudanese government to provide access to affordable pharmaceuticals to people in rural areas.
The pharmaceutical industry in Sudan includes a number of regional businesses that create a variety of pharmaceutical goods, including generic medications, medical equipment, and conventional herbal remedies.
According to UNAIDS, the number of people living with HIV in Sudan is 56,000, corresponding to a prevalence rate of 0.3% in adults aged between 15 and 49. In South Sudan, there are an estimated 180,000 HIV sufferers, which corresponds to a prevalence rate of 2.5%.
Infrastructure, technology, and financial issues are problems that the local sector must deal with. It can be difficult to guarantee access to necessary medications in Sudan, especially in underserved and conflict-affected areas.
Sudan has a large population that practises traditional medicine, and the government has worked to regulate and include these practises into the healthcare system alongside contemporary medications.To increase access to affordable healthcare and medicines, the government and international organisations are working.
The collaborations between the international and local pharmaceutical companies could help to strengthen the Sudanese pharmaceutical industry and improve access to quality pharmaceutical products.
The government seeks to partner with private companies to establish pharmaceutical manufacturing facilities, improve drug distribution networks, and expand access to healthcare services.
National Drug Policy (2018-2027), this comprehensive policy outlines a strategic roadmap for the development of the pharmaceutical sector. It focuses on improving access to essential medicines, promoting local manufacturing, and strengthening regulatory frameworks.
The Sudan pharmaceutical market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Sudanese Government Approves New Investment Incentives for Pharmaceutical Industry: The Sudanese Council of Ministers approved a package of investment incentives aimed at attracting foreign and local investments in the pharmaceutical industry. These incentives include tax breaks, land concessions, and access to financing. (Source: Sudan Tribune)
Sanofi and Sudanese Government Partner to Expand Access to Essential Medicines: Sanofi announced a partnership with the Sudanese government to provide access to affordable essential medicines for people in rural areas. The initiative will focus on distributing key drugs for diabetes, hypertension, and infectious diseases. (Source: Sanofi press release).
Sudanese Pharmaceutical Company Secures Funding for New Manufacturing Facility: El-Nile Pharmaceutical Company announced that it has secured funding for the construction of a new manufacturing facility in Khartoum. The facility will produce generic drugs for local and regional markets. (Source: Business Africa magazine)
Sudanese Government Launches Counterfeit Drugs Control Initiative: The Sudanese government launched a nationwide campaign to combat the circulation of counterfeit and substandard drugs. The initiative includes increased border controls, market surveillance, and public awareness campaigns. (Source: Sudan News Agency)
Takeda Pharmaceutical Company: Introduced a new treatment for inflammatory bowel disease, Entyvio, in adults with moderate to severe Crohn’s disease. ENTYVIO is a biologic treatment for people with ulcerative colitis (UC) or Crohn’s disease. In clinical trials, ENTYVIO helped many people achieve long-term relief and remission.
Boehringer Ingelheim: Introduced Spiolto Respimat, a new inhaler medication for the treatment of chronic obstructive pulmonary disease (COPD).It is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Bristol Myers Squibb: Launched Opdivo, a new immunotherapy drug for the treatment of non-small cell lung cancer.OPDIVO (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) and 2 cycles of chemotherapy that contains platinum and another chemotherapy medicine, as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer)
